Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | SI | P14410 | 1/20 | 0.42 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11126995 | 0.87 | MGAM (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL4204036 | 0.87 | MGAM (0.39) | CNR2MGAMGAASIMGAM2 | |
| SCHEMBL5180093 | 0.87 | MGAM (0.39) | CNR2MGAMGAASIMGAM2 | |
| SCHEMBL5166981 | 0.84 | MGAM (0.37) | CNR2MGAMGAASIMGAM2 | |
| SCHEMBL5327674 | 0.84 | MGAM (0.37) | CNR2MGAMGAASIMGAM2 | |
| SCHEMBL4195616 | 0.84 | MGAM (0.37) | CNR2MGAMGAASIMGAM2 | |
| SCHEMBL4936189 | 0.84 | MGAM (0.37) | CNR2MGAMGAASIMGAM2 | |
| SCHEMBL21327975 | 0.84 | MGAM (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7734523 | 0.84 | ALDH1A1 (0.46) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL5163368 | 0.82 | PLA2G2C (0.43) | MGAMGAASIMGAM2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124820-A1 | C1-Symmetric Bisphospine Ligands and Their Use in the Asymmetric Synthesis of Pregabalin | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| EP-1727620-B1 | C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER LAMBERT CO (US) | 2007-08-29 | — | — | EP | disclosed |
| EP-1727620-A1 | C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN | Warner-Lambert Company LLC (US) | 2006-12-06 | — | — | EP | disclosed |
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | BAO JIAN | 2005-10-13 | — | — | US | disclosed |
| WO-2005087370-A1 | C1-SYMMETRIC BISPHOSPHINE LIGANDS AND THEIR USE IN THE ASYMMETRIC SYNTHESIS OF PREGABALIN | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050228190-A1 | C1-symmetric bisphosphine ligands and their use in the asymmetric synthesis of pregabalin | GABRA5, CNR1, GABRE | CNR2 10/4885MGAM 1482/4885GAA 3774/4885 |
| US-20090124820-A1 | C1-Symmetric Bisphospine Ligands and Their Use in the Asymmetric Synthesis of Pregabalin | GABRE, GABRP, GABRA5 | CNR2 20/4885MGAM 2166/4885GAA 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.